Product Code: ETC8837817 | Publication Date: Sep 2024 | Updated Date: May 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Bhawna Singh | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The oncology-focused NGS market in the Philippines is developing as a specialized diagnostic service. This growth is supported by increasing cancer incidence and greater awareness among physicians about the clinical utility of tumor genetic analysis.
The Philippines clinical oncology NGS market is closely tied to the global advancements in cancer genomics and personalized medicine. NGS technology helps clinicians analyze the genetic makeup of tumors, allowing for more accurate diagnosis and treatment. As cancer care continues to shift towards precision medicine, the market for clinical oncology NGS services is expected to grow, with increasing adoption of these technologies in hospitals and research institutes across the Philippines.
The clinical oncology NGS market faces parallel issues as the broader NGS segment, including lack of trained personnel, cost-prohibitive testing, and limited access outside major metropolitan areas. Institutional hesitancy and ethical concerns around genomic testing and patient consent also inhibit growth. The fragmented nature of cancer care further reduces the likelihood of standardized NGS deployment.
This market supports precision oncology through next-gen sequencing. Investors can provide NGS equipment, analysis services, and diagnostic panels for specific cancers prevalent in the Philippines, such as liver and breast cancer.
The clinical oncology NGS market benefits from policy direction focusing on cancer control and early detection. The National Integrated Cancer Control Act emphasizes early diagnosis and patient-centered care, indirectly encouraging the use of advanced tools like NGS. Government-run cancer hospitals and research programs are being encouraged to adopt such technologies, though full-scale implementation is still in early stages due to cost and infrastructure limitations.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Philippines Clinical Oncology NGS Market Overview |
3.1 Philippines Country Macro Economic Indicators |
3.2 Philippines Clinical Oncology NGS Market Revenues & Volume, 2021 & 2031F |
3.3 Philippines Clinical Oncology NGS Market - Industry Life Cycle |
3.4 Philippines Clinical Oncology NGS Market - Porter's Five Forces |
3.5 Philippines Clinical Oncology NGS Market Revenues & Volume Share, By Technology, 2021 & 2031F |
3.6 Philippines Clinical Oncology NGS Market Revenues & Volume Share, By Workflow, 2021 & 2031F |
3.7 Philippines Clinical Oncology NGS Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.8 Philippines Clinical Oncology NGS Market Revenues & Volume Share, By End-use, 2021 & 2031F |
4 Philippines Clinical Oncology NGS Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Philippines Clinical Oncology NGS Market Trends |
6 Philippines Clinical Oncology NGS Market, By Types |
6.1 Philippines Clinical Oncology NGS Market, By Technology |
6.1.1 Overview and Analysis |
6.1.2 Philippines Clinical Oncology NGS Market Revenues & Volume, By Technology, 2021- 2031F |
6.1.3 Philippines Clinical Oncology NGS Market Revenues & Volume, By Whole Genome Sequencing, 2021- 2031F |
6.1.4 Philippines Clinical Oncology NGS Market Revenues & Volume, By Whole Exome Sequencing, 2021- 2031F |
6.1.5 Philippines Clinical Oncology NGS Market Revenues & Volume, By Targeted Sequencing & Resequencing Centrifuges, 2021- 2031F |
6.2 Philippines Clinical Oncology NGS Market, By Workflow |
6.2.1 Overview and Analysis |
6.2.2 Philippines Clinical Oncology NGS Market Revenues & Volume, By Pre-Sequencing, 2021- 2031F |
6.2.3 Philippines Clinical Oncology NGS Market Revenues & Volume, By Sequencing, 2021- 2031F |
6.2.4 Philippines Clinical Oncology NGS Market Revenues & Volume, By Data Analysis, 2021- 2031F |
6.3 Philippines Clinical Oncology NGS Market, By Application |
6.3.1 Overview and Analysis |
6.3.2 Philippines Clinical Oncology NGS Market Revenues & Volume, By Screening, 2021- 2031F |
6.3.3 Philippines Clinical Oncology NGS Market Revenues & Volume, By Companion Diagnostics, 2021- 2031F |
6.3.4 Philippines Clinical Oncology NGS Market Revenues & Volume, By Other Diagnostics, 2021- 2031F |
6.4 Philippines Clinical Oncology NGS Market, By End-use |
6.4.1 Overview and Analysis |
6.4.2 Philippines Clinical Oncology NGS Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 Philippines Clinical Oncology NGS Market Revenues & Volume, By Clinics, 2021- 2031F |
6.4.4 Philippines Clinical Oncology NGS Market Revenues & Volume, By Laboratories, 2021- 2031F |
7 Philippines Clinical Oncology NGS Market Import-Export Trade Statistics |
7.1 Philippines Clinical Oncology NGS Market Export to Major Countries |
7.2 Philippines Clinical Oncology NGS Market Imports from Major Countries |
8 Philippines Clinical Oncology NGS Market Key Performance Indicators |
9 Philippines Clinical Oncology NGS Market - Opportunity Assessment |
9.1 Philippines Clinical Oncology NGS Market Opportunity Assessment, By Technology, 2021 & 2031F |
9.2 Philippines Clinical Oncology NGS Market Opportunity Assessment, By Workflow, 2021 & 2031F |
9.3 Philippines Clinical Oncology NGS Market Opportunity Assessment, By Application, 2021 & 2031F |
9.4 Philippines Clinical Oncology NGS Market Opportunity Assessment, By End-use, 2021 & 2031F |
10 Philippines Clinical Oncology NGS Market - Competitive Landscape |
10.1 Philippines Clinical Oncology NGS Market Revenue Share, By Companies, 2024 |
10.2 Philippines Clinical Oncology NGS Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |